# Phlow Corporation

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/phlow

- Industry: Pharmaceuticals
- Headquarters: Richmond, US
- Website: www.phlow-usa.com
- Total disclosed funding: $31M
- Latest round: Series C (Jan 31, 2025)
- Investors on record: 1

## About

Based in the US, Phlow Corporation focuses on the development and manufacturing of Active Pharmaceutical Ingredients (APIs) and finished pharmaceutical products, specializing in small molecule formulations to enhance the domestic pharmaceutical supply chain.Phlow Corporation, founded in 2020 and headquartered in Richmond, US, specializes in the production of pharmaceutical ingredients and products. The company has completed three deals, with its most recent deal occurring on April 5, 2023. In this round, Phlow raised USD 36 mn in Series B funding, making this the total amount raised to date. The company is led by CEO Eric Edwards.Phlow Corp. specializes in the development and manufacturing of Active Pharmaceutical Ingredients (APIs) and finished pharmaceutical products, focusing on small molecule formulations. Their state-of-the-art manufacturing infrastructure is designed to support both small and large-scale production for clinical trials and commercial use, ensuring that critical medications are produced entirely on U.S. soil. The company aims to address vulnerabilities in the pharmaceutical supply chain that have arisen from years of outsourcing, particularly concerning the availability of essential medicines. Phlow serves a diverse client base, including government agencies and healthcare providers, with a commitment to restoring pharmaceutical sovereignty in the U.S. market. The geographical markets for Phlow's products extend across the United States, where their offerings are integrated into healthcare systems, addressing pressing public health needs and providing robust solutions during times of crisis.Phlow Corp. operates on a business model that encompasses both contract development and manufacturing services, primarily engaging in B2B transactions with healthcare institutions and government entities. Revenue generation is facilitated through partnerships and contracts that involve the production of critical medicines, including exclusive APIs and finished pharmaceutical products tailored to client specifications. The company’s transaction structure relies heavily on service agreements with governmental bodies, which often involve long-term commitments and milestone-based payments. Phlow's focus on delivering high-quality, reliable medications aligns with their strategy of improving accessibility and affordability in the U.S. medicine supply chain, although specific pricing plans for their trademarked products are not disclosed.In April 2023, Phlow Corporation raised USD 36 mn in Series B funding to support the expansion of its commercial offerings. The company plans to introduce new products aimed at enhancing its portfolio and addressing specific market needs. Additionally, it is targeting further expansion into new geographic regions, although specific markets have not been detailed. The funding will be utilized to bolster these initiatives, ensuring Phlow can meet its growing client demands.

## Funding rounds

- Series C, Jan 31, 2025, $31M — Align Private Capital

## Investors

- Align Private Capital (https://capitalatlas.ai/funds/align-private-capital) — Series C